Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Top Cited Papers
- 15 June 2009
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (12), 4941-4944
- https://doi.org/10.1158/0008-5472.can-09-0547
Abstract
There is increasing evidence that T cells are able to control tumor growth and survival in cancer patients, both in early and late stages of the disease. However, tumor-specific T-cell responses are difficult to mount and sustain in cancer patients, and are limited by numerous immune escape mechanisms of tumor cells selected during immunoediting. An alternative approach to engage T cells for cancer therapy are antibodies, which are bispecific for a surface target antigen on cancer cells, and for CD3 on T cells. These are capable of connecting any kind of cytotoxic T cell to a cancer cell, independently of T-cell receptor specificity, costimulation, or peptide antigen presentation. Here, we review the principle of a new class of bispecific antibodies called BiTE (for “bispecific T-cell engager”) antibodies. Recent results from clinical studies with a CD19/CD3-bispecific BiTE antibody suggest that this therapeutic paradigm is finally showing promise for treatment of both bulky and minimal residual disease. [Cancer Res 2009;69(12):4941–4]Keywords
This publication has 20 references indexed in Scilit:
- Mode of cytotoxic action of T cell-engaging BiTE antibody MT110Immunobiology, 2009
- Nuclear signalling by tumour-associated antigen EpCAMNature, 2009
- Targeted Therapies to Improve Tumor ImmunotherapyClinical Cancer Research, 2008
- BiTE: A new class of antibodies that recruit T-cellsDrugs of the Future, 2008
- Immunosuppressive Strategies that are Mediated by Tumor CellsAnnual Review of Immunology, 2007
- In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumorThe Journal of Experimental Medicine, 2007
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- High Frequency of Functionally Active Melan-A–Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient MelanomaCancer Research, 2004
- Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibodyInternational Journal of Cancer, 2002
- Hybrid antibodies can target sites for attack by T cellsNature, 1985